In this episode of The Oncology Insights Podcast, I speak with Dr. Tony Abraham, President and Medical Director, and Daniel Varghese, CEO of RadiantPath Health, about expanding access to nuclear theranostics in oncology. They explore mobile delivery of Lu-177 PSMA therapy, regulatory and staffing barriers, and patient-centered care models, and examine how bringing advanced treatments into community settings can reduce travel burden and improve therapy completion. Daniel and Dr. Abraham also highlight the role of artificial intelligence, safety standards, and future applications beyond prostate cancer. Listen now on all major platforms!

"Theranostics allows clinicians to precisely identify cancer targets through imaging and then deliver treatment directly to those same sites, minimizing damage to surrounding healthy tissues." - Dr. Tony Abraham

Meet the guests:

Daniel Varghese is a board-certified Physician Assistant and CEO of RadiantPath Health, leading the first mobile nuclear medicine unit in the United States.

Dr. Tony Abraham is a Nuclear Medicine Physician with fellowship training in PET/CT and nuclear oncology, and over 20 years of experience advancing targeted therapeutics in cancer care.

Liked this one? Don’t stop now. Here’s what we think you’ll love!

What you will learn:

• (00:00) Highlight
• (00:42) Introduction
• (07:28) Theranostics explained
• (10:11) Patient experience
• (12:10) Access limitations
• (14:51) Staffing barriers
• (22:43) Mobile scheduling
• (40:38) Final Questions

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The Oncology Insights Podcast

Instagram: The Oncology Insights Podcast

LinkedIn: The Oncology Insights Podcast